Cargando…

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study

Detalles Bibliográficos
Autores principales:	Nam, Chang Hyun, Byun, Ja Min, Shin, Dong-Yeop, Hong, Junshik, Kim, Inho, Yoon, Sung-Soo, Koh, Youngil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478612/ https://www.ncbi.nlm.nih.gov/pubmed/34462405 http://dx.doi.org/10.5045/br.2021.2021067

Ejemplares similares

Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients
por: Ahn, Hyun Jin, et al.
Publicado: (2022)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023)

Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study
por: Hong, Yilei, et al.
Publicado: (2023)

Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients
por: Hamed, Eman Mostafa, et al.
Publicado: (2023)

Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia
por: Lee, Ayoung, et al.
Publicado: (2020)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

Author Correction: Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia
por: Lee, Ayoung, et al.
Publicado: (2020)

New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients
por: Yoon, Jun Seok, et al.
Publicado: (2018)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia
por: Maraziti, Giorgio, et al.
Publicado: (2021)

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome
por: Xu, Liping, et al.
Publicado: (2022)

Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin
por: Seo, Jeongmin, et al.
Publicado: (2021)

Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Serum Erythropoietin level in anemia of elderly with unclear etiology
por: Seong, Ju Yong, et al.
Publicado: (2023)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
por: Nambiar, Vivek, et al.
Publicado: (2016)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
por: Wang, Juan, et al.
Publicado: (2021)

Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis
por: Zhang, Jiaxing, et al.
Publicado: (2018)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
por: Park, Hyunkyung, et al.
Publicado: (2022)

Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report
por: Kim, Hyun-Young, et al.
Publicado: (2019)

Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review
por: Huang, Hsu-En, et al.
Publicado: (2022)

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019)

Cyclical Thrombocytopenia Synchronized With the Patient’s Menstrual Cycle Treated With Danazol
por: Menakuru, Sasmith R., et al.
Publicado: (2022)

Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
por: Kim, Dong Hyun, et al.
Publicado: (2022)

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag
por: Yoon, Jung-Ki, et al.
Publicado: (2019)

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
por: Meng, Fanqiao, et al.
Publicado: (2020)

Eltrombopag Improves Refractory Thrombocytopenia in a Patient with Systemic Lupus Erythematosus
por: Shima, Natsuki, et al.
Publicado: (2018)

Eltrombopag use for refractory immune thrombocytopenia in pregnancy: A case report
por: Weingarten, Sarah J., et al.
Publicado: (2020)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?
por: Byun, Ja Min, et al.
Publicado: (2021)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6k6njjtpmuksmcbs2hshdqparp